Tissue | Expression Dynamics | Abbreviation |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/SP100_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/SP100_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Lung | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Lung/SP100_pca_on_diff_genes.png) | AAH: Atypical adenomatous hyperplasia |
AIS: Adenocarcinoma in situ |
IAC: Invasive lung adenocarcinoma |
MIA: Minimally invasive adenocarcinoma |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/SP100_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Prostate/SP100_pca_on_diff_genes.png) | BPH: Benign Prostatic Hyperplasia |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/SP100_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/SP100_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:000072324 | Thyroid | ATC | telomere maintenance | 76/6293 | 131/18723 | 8.21e-09 | 1.75e-07 | 76 |
GO:004682533 | Thyroid | ATC | regulation of protein export from nucleus | 25/6293 | 30/18723 | 2.87e-08 | 5.44e-07 | 25 |
GO:001063131 | Thyroid | ATC | epithelial cell migration | 169/6293 | 357/18723 | 4.21e-08 | 7.69e-07 | 169 |
GO:009013031 | Thyroid | ATC | tissue migration | 171/6293 | 365/18723 | 8.55e-08 | 1.47e-06 | 171 |
GO:009013231 | Thyroid | ATC | epithelium migration | 169/6293 | 360/18723 | 8.57e-08 | 1.47e-06 | 169 |
GO:190382816 | Thyroid | ATC | negative regulation of cellular protein localization | 67/6293 | 117/18723 | 1.23e-07 | 2.06e-06 | 67 |
GO:005110027 | Thyroid | ATC | negative regulation of binding | 86/6293 | 162/18723 | 2.41e-07 | 3.73e-06 | 86 |
GO:004277016 | Thyroid | ATC | signal transduction in response to DNA damage | 90/6293 | 172/18723 | 3.01e-07 | 4.52e-06 | 90 |
GO:0008625111 | Thyroid | ATC | extrinsic apoptotic signaling pathway via death domain receptors | 50/6293 | 82/18723 | 3.47e-07 | 5.13e-06 | 50 |
GO:003033033 | Thyroid | ATC | DNA damage response, signal transduction by p53 class mediator | 45/6293 | 72/18723 | 4.87e-07 | 7.03e-06 | 45 |
GO:003434015 | Thyroid | ATC | response to type I interferon | 38/6293 | 58/18723 | 6.67e-07 | 9.13e-06 | 38 |
GO:005123532 | Thyroid | ATC | maintenance of location | 152/6293 | 327/18723 | 7.84e-07 | 1.04e-05 | 152 |
GO:001063231 | Thyroid | ATC | regulation of epithelial cell migration | 137/6293 | 292/18723 | 1.44e-06 | 1.77e-05 | 137 |
GO:005145722 | Thyroid | ATC | maintenance of protein location in nucleus | 19/6293 | 23/18723 | 1.89e-06 | 2.29e-05 | 19 |
GO:005165133 | Thyroid | ATC | maintenance of location in cell | 105/6293 | 214/18723 | 1.92e-06 | 2.31e-05 | 105 |
GO:005110133 | Thyroid | ATC | regulation of DNA binding | 64/6293 | 118/18723 | 3.10e-06 | 3.54e-05 | 64 |
GO:1902041110 | Thyroid | ATC | regulation of extrinsic apoptotic signaling pathway via death domain receptors | 32/6293 | 49/18723 | 5.63e-06 | 6.00e-05 | 32 |
GO:007135714 | Thyroid | ATC | cellular response to type I interferon | 33/6293 | 52/18723 | 1.01e-05 | 1.00e-04 | 33 |
GO:006033714 | Thyroid | ATC | type I interferon signaling pathway | 32/6293 | 50/18723 | 1.06e-05 | 1.05e-04 | 32 |
GO:005109022 | Thyroid | ATC | regulation of DNA-binding transcription factor activity | 190/6293 | 440/18723 | 1.49e-05 | 1.39e-04 | 190 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
SP100 | SNV | Missense_Mutation | | c.1561N>A | p.Glu521Lys | p.E521K | P23497 | protein_coding | tolerated(0.06) | benign(0.098) | TCGA-A2-A0CX-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD |
SP100 | SNV | Missense_Mutation | novel | c.1863N>A | p.Phe621Leu | p.F621L | P23497 | protein_coding | tolerated(1) | benign(0.003) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
SP100 | SNV | Missense_Mutation | | c.802N>A | p.Leu268Met | p.L268M | P23497 | protein_coding | deleterious(0.01) | probably_damaging(0.948) | TCGA-AN-A0AK-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
SP100 | SNV | Missense_Mutation | | c.401N>G | p.Tyr134Cys | p.Y134C | P23497 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-AO-A128-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD |
SP100 | SNV | Missense_Mutation | | c.1157N>A | p.Arg386Lys | p.R386K | P23497 | protein_coding | tolerated(0.45) | benign(0.237) | TCGA-BH-A0BZ-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | doxorubicin | CR |
SP100 | SNV | Missense_Mutation | rs373614701 | c.116N>T | p.Thr39Met | p.T39M | P23497 | protein_coding | deleterious(0.02) | possibly_damaging(0.821) | TCGA-BH-A0GZ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | arimidex | SD |
SP100 | SNV | Missense_Mutation | novel | c.1126C>T | p.Pro376Ser | p.P376S | P23497 | protein_coding | tolerated(0.59) | benign(0) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
SP100 | SNV | Missense_Mutation | novel | c.2119G>A | p.Val707Met | p.V707M | P23497 | protein_coding | deleterious(0.04) | possibly_damaging(0.874) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
SP100 | SNV | Missense_Mutation | novel | c.926N>T | p.Cys309Phe | p.C309F | P23497 | protein_coding | tolerated(0.7) | benign(0.048) | TCGA-C5-A8YR-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | PD |
SP100 | SNV | Missense_Mutation | novel | c.125A>G | p.Gln42Arg | p.Q42R | P23497 | protein_coding | deleterious(0.01) | benign(0.069) | TCGA-EA-A97N-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |